Policy, Organisation and Incentives in Health Systems
Health system policies should incentivise high-quality health care in areas of highest need at the lowest feasible cost. Our aim is to expand our understanding of policies that result in healthier populations and achieve sustainability while being responsive to patients’ needs.
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of the antibiotic, regardless of the volume used.
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for widespread access.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.
The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
16 November 2022
A Center for Global Development (CGD) paper authored by OHE’s Adrian Towse and CGD’s Rachel Silverman Bonnifield shows a very high expected return on investment (ROI)…
The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?
12 October 2022
In this fourth and final blog in our AMR series, we set out a positive scenario for tackling antibiotic resistance, and contemplate other possibilities.
The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics
12 October 2022
In the third instalment in our blog series, we think about how the rest of the world can join the effort to stimulate a healthy market for new antibiotics….
The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot
12 October 2022
This second blog focuses on the value assessment used within the NICE-NHS England AMR pilot, which is crucial for capturing an antibiotic’s value so the subscription model can reward those with higher value.
The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance
12 October 2022
Recently the UK became the first country in the world to test a so-called ‘fully delinked model’ to pay for antibiotics. OHE is publishing a series of four blogs to answer the key questions raised by the NICE-NHS England AMR model [and discuss what it means for the future of antibiotic development].
OHE Annual Lecture 2022 | Universal Health Coverage: More Than Just Old Wine in a New Bottle?
6 October 2022
Most countries seem to agree on the desirable goal of UHC: “Everyone—whether rich or poor—should get the care they need without suffering undue financial hardship as a result.”